ReiThera will be involved in setting up both Upstream Process (USP) and Downstream Process (DSP) conditions for GMP-compatible manufacturing of an AAV candidate specifically retargeted to muscle cells with an innovative technological approach, and to produce batches for preclinical studies.
London, July 11, 2023 – We are thrilled to announce the launch of the groundbreaking project “MAGIC” (Next-generation Models And Genetic therapIes for rare neuromusCular diseases). This ambitious four-year initiative jointly funded (~9.5M EUR) by Horizon Europe and UK Research and Innovation (UKRI) brings together 15 international partners to transform the treatment landscape for muscular dystrophies, which are severe genetic disorders with limited treatment options.